EDVANYSEBeveragesFiscal year ends December 31

Endovia Health Sciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026

$0.14−0.01 (-7.53%)

Close on Oct 19, 2026

Market cap: $413.76K
P/E (TTM): –
Dividend yield: –

Endovia Health Sciences, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	0.07	0.80	19	18	11	2.30	0.02	1.31	0.90	1.01	0.90	0.61	0.48	0.31	0.28
Cost of Revenue	–	3.80	13	12	7.40	1.94	0.25	0.61	0.44	0.48	0.43	0.26	0.24	0.13	0.15
Gross Profit	0.02	-0.12	5.57	5.92	3.92	0.36	-0.23	0.70	0.45	0.53	0.47	0.35	0.24	0.18	0.14
Selling, General & Admin	–	–	–	–	–	–	0.20	0.19	0.16	0.14	–	–	–	–	–
Selling & Marketing	0.08	0.48	2.49	2.81	0.79	0.15	0.07	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	0.24	0.19	0.19
Advertising Expenses	0.06	0.49	1.72	0.73	0.73	0.15	0.00	0.02	0.01	0.00	0.00	0.00	0.00	–	–
Operating Expenses	14	9.78	21	27	33	18	4.26	0.64	0.61	0.58	0.45	0.38	0.24	0.19	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	0.19	0.19
Operating Income	-14	-9.90	-15	-21	-29	-18	-4.49	0.07	-0.16	-0.05	0.02	-0.03	0.00	-0.01	-0.05
Interest Expense	2.52	3.70	1.86	0.25	0.44	–	0.01	0.01	0.00	0.00	0.01	0.00	0.00	0.00	0.00
Interest & Investment Income	–	0.00	0.00	0.01	0.00	0.00	0.00	0	–	–	–	–	–	0.00	0.00
Other Non-Operating Income	-10	-7.71	-5.72	-0.25	-0.26	-1.93	-0.65	0.00	0.01	0.00	0.00	0.00	0.00	–	–
Asset Impairment Charges	4.30	4.30	–	–	–	9.50	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	0.00	0.01	0.01	0.01	0.01	0.00	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	–	–	–	–	–
Income from Continuing Operations	–	-24	-21	-22	-29	-20	-5.14	–	–	–	–	–	–	–	–
Income from Discontinued Operations	-0.89	-6.15	0	-0.20	0.29	-9.09	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-25	–	–	-22	-29	29	-5.14	0.07	–	–	–	–	–	–	–
Net Income	-25	-24	-21	-22	-29	-29	-5.14	0.07	-0.15	-0.05	0.02	-0.03	-0.03	-0.01	-0.05
Net Income to Common	-26	-24	–	-22	-29	-29	-0.48	0.07	–	–	–	–	–	–	–
EPS (Basic)(per share)	-47.88	-70.72	–	–	-163.20	-169.60	-20.80	0.49	-0.49	0.00	0.00	0.00	0.00	0.00	-0.49
EPS (Diluted)(per share)	-47.88	-70.72	–	–	-163.20	-169.60	-20.80	0.49	-0.49	0.00	0.00	0.00	0.00	0.00	-0.49
Shares Outstanding (Basic, Weighted)(shares)	0.54	0.33	0.27	0.23	–	0.35	0.26	0.23	0.23	0.21	0.20	0.20	0.20	0.19	0.16
Shares Outstanding (Diluted, Weighted)(shares)	0.54	0.33	0.27	0.23	0.18	0.12	0.26	0.23	0.23	0.21	0.20	0.20	0.20	0.19	0.16
EBITDA	-14	-9.50	-15	-20	-29	-18	-4.48	–	–	–	–	–	–	–	–
Net Interest Income	-2.52	-3.70	-1.85	–	-0.44	-1.98	-0.67	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 34.7%
Operating margin: -18486.6%
Net margin: -23653.4%
Return on equity, FY2025: 148.7%

Financial strength

Current ratio: 0.05
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1.4%

Valuation

P/E ratio: –
Price to sales: 5.66
Price to book: –
Dividend yield: –